Medical/Pharmaceuticals

No Picture
News

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

June 24, 2020 sandiegobiotech Comments Off on DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

SAN DIEGO, June 24, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 l… […]

No Picture
News

Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 16, 2020 sandiegobiotech Comments Off on Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, June 16, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing o… […]

No Picture
News

Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

June 16, 2020 sandiegobiotech Comments Off on Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

SAN DIEGO, June 16, 2020 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyT… […]

No Picture
News

Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital

June 16, 2020 sandiegobiotech Comments Off on Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital

SAN DIEGO, June 16, 2020 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorec… […]

No Picture
News

Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

June 15, 2020 sandiegobiotech Comments Off on Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

Live Webcast will be on June 22, 2020

SAN DIEGO, June 15, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22… […]

No Picture
News

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

June 15, 2020 sandiegobiotech Comments Off on Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

– Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels- 3 (60%) of the 5 patients remain on treatment with durable response d… […]